658 related articles for article (PubMed ID: 27931835)
1. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
4. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
Tewari KS; Monk BJ
Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A; Cetina L; Coronel J; Martínez-Baños D
Drugs; 2010 Mar; 70(4):403-32. PubMed ID: 20205484
[TBL] [Abstract][Full Text] [Related]
6. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
8. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
Tambaro R; Scambia G; Di Maio M; Pisano C; Barletta E; Iaffaioli VR; Pignata S
Crit Rev Oncol Hematol; 2004 Oct; 52(1):33-44. PubMed ID: 15363465
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials.
Seol HJ; Ulak R; Ki KD; Lee JM
Tohoku J Exp Med; 2014 Apr; 232(4):269-76. PubMed ID: 24695215
[TBL] [Abstract][Full Text] [Related]
11. Management of advanced or recurrent cervical cancer: chemotherapy and beyond.
Elit LM; Hirte H
Expert Rev Anticancer Ther; 2014 Mar; 14(3):319-32. PubMed ID: 24428511
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for advanced, recurrent, and metastatic cervical cancer.
Moore DH
J Natl Compr Canc Netw; 2008 Jan; 6(1):53-7. PubMed ID: 18267059
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
14. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
15. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
16. Advances in cervical cancer pharmacotherapies.
Markman M
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):219-23. PubMed ID: 24490716
[TBL] [Abstract][Full Text] [Related]
17. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
18. New pharmacotherapy options for cervical cancer.
Dueñas-Gonzalez A; Cetina L; Coronel J; Cano C; Dolores R
Expert Opin Pharmacother; 2014 Jan; 15(1):51-60. PubMed ID: 24206031
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
[TBL] [Abstract][Full Text] [Related]
20. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
